These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18224685)

  • 1. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
    Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
    Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
    Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
    Barault L; Charon-Barra C; Jooste V; de la Vega MF; Martin L; Roignot P; Rat P; Bouvier AM; Laurent-Puig P; Faivre J; Chapusot C; Piard F
    Cancer Res; 2008 Oct; 68(20):8541-6. PubMed ID: 18922929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
    Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
    Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
    Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
    Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
    Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
    Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
    Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
    Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
    Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
    BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
    Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.
    Levidou G; Saetta AA; Gigelou F; Karlou M; Papanastasiou P; Stamatelli A; Kavantzas N; Michalopoulos NV; Agrogiannis G; Patsouris E; Korkolopoulou P
    World J Surg Oncol; 2012 Feb; 10():47. PubMed ID: 22376079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
    Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
    Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.
    Oikonomou E; Makrodouli E; Evagelidou M; Joyce T; Probert L; Pintzas A
    Neoplasia; 2009 Nov; 11(11):1116-31. PubMed ID: 19881948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.
    Berg M; Guriby M; Nordgård O; Nedrebø BS; Ahlquist TC; Smaaland R; Oltedal S; Søreide JA; Kørner H; Lothe RA; Søreide K
    Mol Med; 2013 Sep; 19(1):286-93. PubMed ID: 23979710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.